at Investor's Business Daily (Tue, 11:57AM)
Next stop Biogen: Carl Icahn's fight for seats on the board of Biogen Idec (BIIB) comes to a...
Next stop Biogen: Carl Icahn's fight for seats on the board of Biogen Idec (BIIB) comes to a vote Wednesday, June 3. He owns 5.6% of the biotech group. Proxy advisory service RiskMetrics Group is backing two of Icahn's nominees. Icahn gained a seat on Amylin's (AMLN) board this week and is lobbying to ouster top management at Enzon (ENZN).
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 8:44AM)
at CNBC.com (Jan 20, 2015)
at CNBC.com (Jan 15, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs